Bergen

• A Placebo-Controlled, Randomized Double-Blind Parallel Group 12-Month Trial of Fasudil for the Treatment of Early Alzheimer’s Disease Recruiting
  2023-506514-44-00 4 2024-06-11 Alzheimer's disease
• A Phase 3 study of Dostarlimab as Sequential Therapy after Chemoradiation compared to placebo in adult participants with Locally Advanced Un … Recruiting
  2023-508613-17-00 5 2024-05-29 Neoplasms, Head and Neck
• A phase 1/2 multicenter open-label study to investigate treatment of hydroxyurea (HU) in combination with valproic acid (VPA) or 6- mercapto … Recruiting
  2022-501992-15-00 9 2024-05-21 Acute Myeloid Leukemia (AML)
• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting
  2023-503631-18-01 5 2024-05-20 Nervous system diseases
• Antibiotic THErapy iN vIral Airway iNfections (ATHENIAN): An open labelled randomized controlled pragmatic trial to evaluate the efficacy an … Recruiting
  2023-509286-20-00 6 2024-05-15 Viral respiratory tract infection
• Atorvastatin in episodic migraine Recruiting
  2022-502176-23-01 4 2024-05-13 Migraine
• Atorvastatin in chronic migraine (StainMigChronic) Recruiting
  2022-502177-42-02 4 2024-05-13 Chronic migraine
• SMART-MS Recruiting
  2023-510228-63-00 4 2024-05-01 Multiple sclerosis
• A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe … Recruiting
  2023-503412-33-00 5 2024-03-29 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cance
• Chiropractic spinal manipulative therapy for acute neck pain: a 4-armed clinical placebo randomized controlled trial Recruiting
  2023-509624-17-00 6 2024-03-08 Acute neck pain
• Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients with Cardiogenic Shock f … Recruiting
  2024-510892-40-00 6 2024-02-29 Acute myocardial infarction complicated by cardiogenic shock
• A Phase 1 study of LOXO-435 in Locally Advanced or Metastatic Solid Tumors with FGFR3 Gene Alterations Recruiting
  2022-502755-59-00 1 2023-08-30 Locally Advanced or Metastatic Solid Tumors with FGFR3 Alterations
• The AMIC study Recruiting
  2022-500586-27-00 6 2023-08-15 Chronic wet cough in young children
• The CORTAD study Recruiting
  2024-512888-31-00 11 2023-08-03 Primary adrenal insufficiency (PAI)
• CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML) Recruiting
  2023-504999-25-00 5 2023-07-14 Acute Myeloid Leukemia
• Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3) Recruiting
  2022-500587-35-01 5 2023-07-06 Stroke
• A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF Class 1 and Class 2 alterations, in participan … Recruiting
  2024-513578-23-00 4 2023-03-21 Tumors harboring BRAF alterations
• SACK Recruiting
  2022-501600-10-00 5 2023-02-07 Atrial fibrillation and Chronic Kidney Disease stage 5
• A study of tucatinib with trastuzumab and mFOLFOX6 versus standard of care treatment in first-line HER2+ metastatic colorectal cancer Recruiting
  2024-514180-25-00 5 2022-11-21 unresectable or metastatic HER2+ colorectal cancer
• Benzodiazepine stabilizing treatment for patients with benzodiazepine dependence undergoing opioid agonist therapy (BMX-BAR) Recruiting
  2023-510404-44-02 5 2022-10-02 Comorbid dependencies to benzodiazepines and opioids
• Sotorasib in advanced KRAS G12C-mutated non-small cell lung cancer patients with comorbidities (SOLUCOM) Recruiting
  2023-503174-20-00 4 2022-05-30 KRAS G12C-mutated non-small cell lung cancer
• A study to evaluate long-term Infigratinib in children with Achondroplasia Recruiting
  2024-513857-55-00 4 2022-02-08 Achondroplasia
• Efficacy of Hyperbaric oxygen in addition to standard treatment for acute sudden deafness Recruiting
  2024-510798-84-00 10 2022-01-28 Idiopathic sudden sensorineural hearing loss (ISSNHL)
• SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years. Recruiting
  2024-510578-25-00 5 2021-11-05 Histologically proven high-risk medulloblastoma, with any of the curre

Showing 97–120 of 235 trials